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The Role of High Molecular Weight Kininogen (Fitzgerald Factor)
in the Activation of Various Plasma Proteolytic Enzyme Systemst
R. Waldmann, DO,* A. G. Scicli, PhD,** J. Guimaraes, PhD,** G . Scicli, PhD,** O. A. Carretero,
MD,** H. Kato, PhD,***, Y. N. Han, PhD,*** and S. Iwanaga, PhD***

Bovine high molecular weight kininogen (bHMWK) partially corrects the aPTT of Eitzgerald-trait plasma, which is
congen ital ly deficient in HMWK. The relationship between
the structure and activity of HMWK was clarified by studying the effects of different fragments of bHMWK on the
aPTT of Fitzgerald-trait plasma. The peptides studied, all in
equimolar
concentrations,
were
lys-bradykinin-free
HMWK, bradyk In In-fragment
1-2-tree HMWK, heavy
chain, fragment 1 -2-Hght chain, and light chain. Bradykinin-fragment 1-2-free HMWK, heavy chain, and light
chain have little or no correcting activity upon Eitzgeraldtrait plasma aPTT. Fragment 1-2 light chain has the same
correcting activity as intact bHMWK, while that of lysbradykinin-free HMWK appears to be higher. Both frag-

ment 1-2 and fragment 2 inhibit the clotting time of normal
human plasma. On a molar basis, fragment 2 is a more
active inhibitor than fragment 1-2. Bovine plasma kallikrein
released kinins from both bHMWK and hHMWK; however,
while the correcting activity of bHMWK was completely
destroyed after sixty minutes of incubation, that of hHMWK
was fully retained. These data suggest that: (1) the active
part of bHMWK is comprised of the fragment 1-2 light
chain portion; (2) fragment 1-2 or fragment 2 is the binding
site to negatively charged surfaces, while the light chain
interacts with other components of the surface-mediated
reactions; and (3) bovine plasma kallikrein releases kinins
but probably does not cause the release of fragment 1-2
from hHMWK.

w
hen normal plasma comes in contact with negatively
charged surfaces such as glass, kaolin, and connective
tissue, a group of plasma proteolytic enzymes is activated.
The proteins that have been identified as being involved in
this contact reaction are: Hageman factor (factor Xll),
Fletcher factor (prekallikrein), and Fitzgerald factor (high
molecular weight kininogen, HMWK). The interaction of
these plasma proteins on a negatively charged surface
results in the activation of factor XI, prekallikrein, and
plasminogen (1-11). Congenital deficiencies in any of these
proteins result in abnormalities of the intrinsic clotting and
fibrinolytic pathways and in the formation of kinins (5-11).

a necessary component for the activation by contact of the
above mentioned proteolytic pathways. Data from our
laboratory (12) and from others (13) have shown that purified bovine high molecular weight kininogen (bHMWK)
partially corrects the prolonged activated plasma thromboplastin time (aPTT) and the kaolin-activated euglobulinlysis time of Fitzgerald-trait plasma. Several investigators
have found that, w h i l e hydrolysis of human H M W K
(hHMWK) by human plasma kallikrein results in kinin
release, the ability of kinin-free HMWK to correct the
abnormalities of Fitzgerald-trait plasma is not affected (11,
14,15). Hydrolysis of bHMWK by bovine plasma kallikrein
results in the release of a large peptide (fragment 1-2) as
w e l l as b r a d y k i n i n . The bradykinin-fragment 1-2 free
bHMWK had almost no correcting activity when tested on
Fitzgerald-trait plasma (12,13). These differences in the
correcting activity of both human and bovine kininogens
after hydrolysis may be due to a lack of fragment 1-2
cleavage from the hHMWK by plasma kallikrein.

Until the Fitzgerald-trait (HMWK deficiency) was discovered (8), the only known role of HMWK was as a
substrate for plasma kallikrein. Now, it is also recognized as

T Supported in part by a grant from the Michigan Heart Association. These
data were presented at the VI International Congress on Thrombosis and
Haemostasis in Philadelphia, 1977 (Thrombos Haemost 1977; 38:14).

To determine whether fragment 1-2 is necessary for
bHMWK correcting activity, our laboratory tested kininfree bHMWK with intact fragment 1-2 for its correcting
activity upon the aPTT of Fitzgerald-trait plasma. Also, to
examine whether bovine plasma kallikrein decreases the
correcting activity of hHMWK, we incubated these two
proteins and determined the correcting activity of the
mixture.
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To clarify the relationship between the structure and the
function of HMWK, the correcting activity of various isolated fragments of bHMWK was studied. Since we previously reported that fragment 2 (histidin rich fragment) has
an inhibitory effect upon the clotting time of normal human
plasma, we also studied the inhibitory activity of fragment
1-2.

Comparison of the correcting activity of bHMWK and its
fragments on the aPTT of Fitzgerald-trait plasma on a
molar and on a weight basis
Intact b H M W K (M.W. 76,000), lys-bradykinin-free
bHMWK (M.W. 75,000), bradykinin-fragment 1-2-free
bHMWK (M.W. 66,000), and fragment 1-2-light chain
(M.W. 48,500) were dissolved in Owren's buffer at concentrations of 1.32, 0.26, and 0.13 n M o l / m l . The correcting activity of 0.1 ml of each solution was tested upon
Fitzgerald-trait plasma aPTT. Simultaneously, the correcting
activity of serial dilutions of a pool of normal human
plasma and its fragments was determined. We then used
this curve to calculate the correcting activity of bHMWK
and its fragments in U / n M o l . One unit of correction is
defined as the correcting activity of 200 p.\ of normal
human plasma.

Materials and Methods
Reagents and chemicals
Sodium barbital, NaCl, acid-washed kaolin (Fisher Scientific Company, Pittsburgh, PA), and CaCb anhydrous (J.T.
Baker Chemical Products, Clifton, Nj) were commercially
obtained. Mr. Fitzgerald himself provided us with HMWK
deficient plasma. Nine parts of blood were mixed with one
part of 3.8% sodium citrate. Plasma was separated by
centrifugation, distributed in 3 ml aliquots in polystyrene
tubes, and kept frozen at - 7 0 ° C .

To compare the correcting activity of bHMWK and its
fragments on a weight basis, 100 p.g of each of the prelyophilized test materials were dissolved in 1.0 ml of
Owren's buffer, and 0.1 ml was used to determine their
correcting activity upon Fitzgerald plasma aPTT.

Purified bovine proteins
Intact bHMWK, Lys-bradykinin-free HMWK, bradykininfragment 1-2 free HMWK, fragment 1-2, fragment 2, and
plasma kallikrein were obtained as previously described
(16-18). Heavy chain and light chain were obtained by
reduction and alkylation of the bradykinin-fragment 1-2
free bHMWK. Fragment 1-2-light chain was similarly obtained from the lys-bradykinin-free bHMWK (18). Purified
hHMWK was obtained by modifying the method of Pierce
and Guimaraes (19).

Effects of bovine plasma kallikrein on the correcting activity of human and bovine HMWK
Purified bovine plasma kallikrein (0.28 p.g] and hHMWK
(95 p.g) were dissolved in 1.0 ml of Owren's buffer (pH 7.5)
and incubated at 37°C for thirty and sixty minutes. At both
times two aliquots of 20/u,l each ofthe incubation mixture
were taken. One was diluted by mixing it with 80 p.\ of
Owren's buffer, and the correction upon the aPTT of
Fitzgerald-trait plasma was tested immediately. The second
aliquot was mixed with 1.980 p,\ of a solution of 0.1 M SBTl
in 0.1 M Tris-HCl buffer (pH 7.4). This mixture was immersed in a boiling water bath for ten minutes, centrifuged, and
the kinins measured. The same procedure was followed
with bHMWK (50 pg) except that 100 p.\ of undiluted
incubation mixture was used for testing its Fitzgerald correcting activity. When human and bovine HMWK were
incubated with Trypsin (20), they released 4.7 and 80 p,g of
kinins/ mg of protein, respectively. Kinins were tested by an
RIA (21).

Kaolin aPTT
The correcting activity of HMWK and its fragment on the
aPTT of Fitzgerald plasma were tested by adding the following in a polystyrene tube: 0.1 ml of Fitzgerald plasma,
0.1 ml ofthe test substance in Owren's buffer, and 0.1 ml of
cephalin-kaolin suspension (10 mg of acid-washed kaolin
suspended in 1.0 ml of cephalin). After this mixture was
pre-incubated at 37°C for eight minutes, 0.1 ml of 0.02 M
CaCl2 was then added and the clotting time determined.

Inhibition of the aPTT of normal plasma by fragment 1-2
and fragment 2

Results

Cephalin-kaolin suspension (0.1 ml) was incubated for one
minute with an Owren's buffer solution of the fragment to
be tested (0.1 ml). Normal plasma (0.1 ml) was added and
the mixture incubated for three minutes. After 0.02 M
CaClj (0.1 ml) had been added, the clotting time was
determined.

The correcting activity of the different purified bovine
proteins, when expressed in U / n M o l , was not affected by
the three different concentrations tested (Tables l-IV). The
exception to this result was lys-bradykinin-free bHMWK, in
which the specific activity doubled with a ten-fold dilution.
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As expected, we found that the heavy chain of bHMWK
has little or no correcting activity, since it is chemically and
immunologically common to both low and high molecular
weight kininogen; low molecular weight kininogen lacks
correcting activity (12). Although the heavy chain is not
essential to express the coagulant activity of bHMWK, it
may play a permissive role, since lys-bradykinin-free
bHMWK (which includes both the heavy chain and the
fragment 1-2-light chain) is more active on a molar basis
than fragment 1-2-light chain (Table I). It is also more active
than intact bHMWK. Lys-brady-kinin-free bHMWK may
have a better steric relationship with Hageman factor
and/or prekallikrein and factor XI than fragment 1-2-light
chain or bHMWK (Table II), thus favoring a more effective
. interaction on the surface.

TABLE I
Molar C o m p a r i s o n of Correcting Activity of
Bovine HMWK and Its Fragments

% of normal
plasma

U/nMol

HMWK

2.5

0.10

Lys-bradykinin-free HMWK

5,6

0.22

Bradykinin and fragment
1-2-free HMWK

0.8

0.03

Fragment 1-2-light chain

2.5

0.10

Light chain

0.1

0.004

Heavy chain

No activity

Protein

0

All proteins were tested at 0.26 nMol / ml
T A B L E II

We have observed an increase in the specific activity of
lys-bradykinin-free bHMWK with higher dilutions. This
increase may be due to the presence of trace amounts of a
contaminant with inhibiting capacity, such as fragment 1-2
or fragment 2, in the preparation.

Weight C o m p a r i s o n of Correcting Activity of
Bovine HMWK and F r a g m e n t s
Protein

U/mg

HMWK

1.2

Lys-bradykinin-free HMWK

1.7

B r a d y k i n i n and f r a g m e n t 1-2 free HMWK

0.3

Fragment 1-2-light chain

2,6

Light chain

0.1

Heavy chain

0

Fragment 1-2

Inhibits

Fragment 2

Inhibits

Fragment 1-2-light chain was obtained by reduction of the
disulfide bonds of the lys-bradykinin-free bHMWK, followed by alkylation of the thiol groups. It retains full
activity in the coagulation assay, which suggests that intact
disulfide bonds are not necessary forthe Fitzgerald correcting activity of bHMWK.

T A B L E III
Inhibitory Effects of Fragment 1-2 and
Fragment 2 on Normal Human P l a s m a a P T T

All proteins were tested at 100 / i g / ml

nM / ml

a PTT
seconds

Fragment 2 (M.W. 4,600)

21.7

320

Fragment 1-2 (M.W. 12,600)

19.8
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Discussion
High molecular weight kininogen seems to be essential for
the contact activation ofthe intrinsic coagulation pathway
(22). To determine which region of the HMWK molecule is
responsible for the correction of Fitzgerald-trait plasma
aPTT, we have used bHMWK, which is known to partially
correct the abnormalities in the aPTT of HMWK-deficient
human plasma (12,13).

Normal plasma aPTT was 45 seconds.

T A B L E IV

Intact bHMWK has a molecular weight of about 76,000
daltons. Of these, 48,500 are contributed by the heavy
chain, 1,000 by bradykinin, 12,600 by fragment 1-2, and
16,000 by the light chain (17). Since the fragments of
bHMWK are present in the intact molecule in equimolar
concentrations, their activity must be expressed on a molar
basis in order to compare their relative correcting activity.

Effect of Bovine P l a s m a Kallikrein on
Correcting Activity of Human and Bovine HMWK

Time of
incubation
(min)

Our findings indicate that a peptide formed by fragment
1-2-light chain is responsible for the Fitzgerald correcting
activity of bHMWK. Fragment 1-2-light chain is as active as
intact bHMWK on a molar basis and virtually more than
twice as active on a weight basis.
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Human
HMWK

Human
HMWK
and bovine
kallikrein

Bovine
HMWK

Bovine
HMWK
and bovine
kallikrein

91

103

0

73

71

30

72

74 (240)

60

76

72

149(265)
0£

200

Number indicates aPTT in seconds. Numbers in parentheses indicate n g o f
kinins released by bovine plasma kallikrein.
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The light chain without fragment 1-2 lacks functional activity, indicating that the fragment 1-2 peptide, or part of it
(fragment 2), plays a crucial role in initiating the intrinsic
coagulation system. Itwas also observed that fragment 1-2
and, to a greater degree, fragment 2 have a marked capacity to inhibit the surface activation of the coagulation
pathways of normal human plasma, butonly ifthe fragment
1-2 or fragment 2 were added before or during the incubation of normal plasma with kaolin. This observation suggests that when fragment 1-2 and fragment 2 bind to the
negatively charged surface, they competitively inhibit the
binding and activation of the proteins involved in the
intrinsic coagulation pathway (Table 111).

tural variations between both substrates. The fact that the
bovine plasma has only 7-12% (12,26) of the correcting
activity of human plasma also points to partial structural
differences between bHMWK and hHMWK. Furthermore,
we have found that if fragment 1-2 remains attached to the
light chain of bHMWK, the Fitzgerald correcting activity is
also retained. Since hHMWK retains full correcting activity
after hydrolysis with bovine or human plasma kallikrein,
we conclude that neither enzyme is able to separate the
basic peptide, equivalent to fragment 1-2, from hHMWK.
Recent evidence indicates that human kininogen shares the
same basic structures w i t h its bovine counterpart.
Nagasawa, et al (27) have reported that hHMWK is a linear
glycoprotein in which the bradykinin moiety is included in
the inner portions. Human kallikrein acts upon hHMWK,
releasing b r a d y k i n i n and leaving a kinin-free H M W K
which has a heavy and a light chain linked by a disulfide
loop, as in bHMWK. It has been shown that antibodies
against human low molecular weight kininogen (hLMWK)
cross-react with hHMWK (19,28). Similarly, antibodies
against bLMWK cross-react with bHMWK (17).

Considering these results, we propose thatthe fragment 1-2
portion serves to bind HMWK to the negatively charged
surfaces, and that the light chain, or part of it, interacts with
Hageman factor and/or prekallikrein and factor XI. Furthermore, since Wiggins, et al (23) have clearly shown that
the activation of factor XI occurs only on the surface, we
propose that the light chain without fragment 1-2 (binding
site) lacks activity because it will remain in the fluid phase.
It may be speculated that HMWK complexed with prekallikrein and factor XI in the fluid phase (24,25) can
"carry" these proteins to negatively charged surfaces. On
the surface, the interaction between Hageman factor,
HMWK, prekallikrein, and factor XI will activate all the
Hageman dependent pathways, such as intrinsic coagulat i o n , f i b r i n o l y t i c , k a l l i k r e i n - k i n i n , and c o m p l e m e n t
systems.

It is known that both bLMWK and hLMWK lack correcting
activity upon Fitzgerald-trait plasma aPTT (10-13). Antibodies against hHMWK, after adsorption with Fitzgeraldtrait plasma (which has LMWK), no longer cross-react with
hLMWK. When tested against hHMWK, a precipitation line
is observed (14,29), which suggests the presence of antigenic determinants in the HMWK molecule not present in
the LMWK. It is logical to assume that these antigenic
determinants are responsible for the HMWK coagulating
activity.

There are some differences as well as similarities between
bovine and human HMWK. Bovine plasma kallikrein destroys the correcting activity of bHMWK, while human
plasma kallikrein does not affect the activity of hHMWK.
This difference may be due to an enzymatic contamination
in the bovine plasma kallikrein preparation (Table IV).
When hHMWK was incubated with bovine kallikrein,
kinins were released, although there was no loss of functional activity. It is therefore unlikely that a contaminating
enzyme is present in the bovine plasma kallikrein preparation, unless the hypothetical contaminating enzyme has
species specificity. It is more probable that the different
behavior of bHMWK and hHMWK after hydrolysis with
homologous plasma kallikrein can be explained by struc-

Komiya, et al (16) and Kato, et al (17) have reported that the
bLMWK and bHMWK differ in their light chains, and we
have shown that the correcting activity of the bHMWK
resides precisely in the fragment 1-2 light chain. To complete the resemblance between the bovine and human
kininogen, it has been reported (29) that the light chain
enables the hHMWK to correct the aPTT of Fitzgerald-trait
plasma. However,a positively charged peptide similar to
the bovine fragment 1-2 has yet to be identified in the light
chain o f t h e hHMWK.
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